Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cidara Thera (CDTX)

Cidara Thera (CDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,925,695
  • Shares Outstanding, K 31,439
  • Annual Sales, $ 1,280 K
  • Annual Income, $ -169,830 K
  • EBIT $ -195 M
  • EBITDA $ -194 M
  • 60-Month Beta 1.46
  • Price/Sales 5,426.49
  • Price/Cash Flow N/A
  • Price/Book 13.21

Options Overview Details

View History
  • Implied Volatility 7.54% (-0.69%)
  • Historical Volatility 207.15%
  • IV Percentile 3%
  • IV Rank 0.27%
  • IV High 340.52% on 06/17/25
  • IV Low 6.65% on 11/24/25
  • Expected Move (DTE 9) 2.00 (0.91%)
  • Put/Call Vol Ratio 0.51
  • Today's Volume 244
  • Volume Avg (30-Day) 3,587
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 47,311
  • Open Int (30-Day) 39,060
  • Expected Range 217.91 to 221.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.36
  • Number of Estimates 3
  • High Estimate -1.24
  • Low Estimate -1.45
  • Prior Year -5.38
  • Growth Rate Est. (year over year) +74.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.14 +115.29%
on 11/11/25
221.20 -0.59%
on 12/03/25
+116.11 (+111.87%)
since 11/10/25
3-Month
62.86 +249.83%
on 09/11/25
221.20 -0.59%
on 12/03/25
+156.46 (+246.63%)
since 09/10/25
52-Week
15.22 +1,344.84%
on 04/07/25
221.20 -0.59%
on 12/03/25
+197.74 (+891.90%)
since 12/10/24

Most Recent Stories

More News
These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now

Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities....

MRK : 97.70 (+0.84%)
CDTX : 219.83 (-0.21%)
DUK : 114.23 (-0.88%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI

NEW YORK , Dec. 8, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

RYI : 24.07 (+3.00%)
MRSN : 28.37 (+0.82%)
SMLR : 20.45 (+0.39%)
CDTX : 219.83 (-0.21%)
Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

RMBI : 14.12 (+2.02%)
GIFI : 11.92 (+0.17%)
MOVE : 8.67 (+13.04%)
CDTX : 219.83 (-0.21%)
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN

NEW YORK , Nov. 27, 2025 / PRNewswire/ --

SEE : 41.60 (+0.31%)
MRSN : 28.37 (+0.82%)
EXAS : 101.28 (+0.03%)
CDTX : 219.83 (-0.21%)
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere...

CDTX : 219.83 (-0.21%)
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX

NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of...

NUVSF : 13.5100 (-0.22%)
NDTAF : 19.9200 (+42.29%)
CDTX : 219.83 (-0.21%)
THS : 23.80 (+0.21%)
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

Merck's multi-billion-dollar acquisition of Cidara Therapeutics is a strategic move to secure a new era of growth with a high-potential antiviral asset.

MRK : 97.70 (+0.84%)
CDTX : 219.83 (-0.21%)
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

SEE : 41.60 (+0.31%)
MRSN : 28.37 (+0.82%)
RPTX : 2.15 (-0.46%)
CDTX : 219.83 (-0.21%)
Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Cidara Therapeutics...

MRK : 97.70 (+0.84%)
CDTX : 219.83 (-0.21%)
Stocks Settle Mixed as Fed Comments Suggest a Rate Cut Pause

The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.06%. December E-mini...

GOOGL : 320.38 (+1.04%)
MPC : 192.27 (+0.81%)
AAPL : 278.96 (+0.64%)
CVX : 151.43 (+1.98%)
ADI : 281.65 (+1.96%)
NU : 16.71 (+0.18%)
STUB : 13.88 (+6.04%)
TXN : 181.59 (+1.15%)
$IUXX : 25,823.75 (+0.60%)
DASH : 221.33 (-3.77%)
ASML : 1,119.62 (+0.74%)
ZNH26 : 112-135 (+0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

3rd Resistance Point 221.02
2nd Resistance Point 220.66
1st Resistance Point 220.48
Last Price 219.83
1st Support Level 219.93
2nd Support Level 219.57
3rd Support Level 219.39

See More

52-Week High 221.20
Last Price 219.83
Fibonacci 61.8% 142.52
Fibonacci 50% 118.21
Fibonacci 38.2% 93.90
52-Week Low 15.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar